Innate Pharma Stock Working Capital
| IPH Stock | EUR 1.43 0.10 6.54% |
Innate Pharma fundamentals help investors to digest information that contributes to Innate Pharma's financial success or failures. It also enables traders to predict the movement of Innate Stock. The fundamental analysis module provides a way to measure Innate Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Innate Pharma stock.
Innate |
Innate Pharma Company Working Capital Analysis
Innate Pharma's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Innate Pharma Working Capital | 192 M |
Most of Innate Pharma's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Innate Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
According to the company's disclosures, Innate Pharma has a Working Capital of 192 M. This is 54.89% lower than that of the Biotechnology sector and 64.35% lower than that of the Health Care industry. The working capital for all France stocks is 87.01% higher than that of the company.
Innate Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Innate Pharma's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Innate Pharma could also be used in its relative valuation, which is a method of valuing Innate Pharma by comparing valuation metrics of similar companies.Innate Pharma is currently under evaluation in working capital category among its peers.
Innate Fundamentals
| Return On Equity | -0.17 | |||
| Return On Asset | -0.043 | |||
| Profit Margin | (0.40) % | |||
| Operating Margin | (0.33) % | |||
| Current Valuation | 86.87 M | |||
| Shares Outstanding | 80.2 M | |||
| Shares Owned By Insiders | 22.50 % | |||
| Shares Owned By Institutions | 10.56 % | |||
| Price To Earning | 125.20 X | |||
| Price To Book | 1.43 X | |||
| Price To Sales | 3.04 X | |||
| Revenue | 12.11 M | |||
| Gross Profit | (22.3 M) | |||
| EBITDA | (47.9 M) | |||
| Net Income | (52.81 M) | |||
| Cash And Equivalents | 103.76 M | |||
| Cash Per Share | 2.62 X | |||
| Total Debt | 46.5 M | |||
| Debt To Equity | 2.70 % | |||
| Current Ratio | 1.62 X | |||
| Book Value Per Share | 1.46 X | |||
| Cash Flow From Operations | (58.46 M) | |||
| Earnings Per Share | (0.27) X | |||
| Target Price | 6.7 | |||
| Number Of Employees | 213 | |||
| Beta | 0.33 | |||
| Market Capitalization | 224.71 M | |||
| Total Asset | 267.5 M | |||
| Retained Earnings | (7 M) | |||
| Working Capital | 192 M | |||
| Current Asset | 252 M | |||
| Current Liabilities | 60 M | |||
| Z Score | 2.4 | |||
| Net Asset | 267.5 M |
About Innate Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Innate Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Innate Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Innate Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Innate Stock
When determining whether Innate Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Innate Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Innate Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Innate Pharma Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innate Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.